Linnaeus Therapeutics

LNS8801, GPER agonist, aging, healthspan

USprivateest. 2016linnaeusbio.com (opens linnaeusbio.com)Checked 10 Oct

The brief

Analyst view
  • Linnaeus is a Penn spinout founded in 2016. LNS8801 activates estrogen receptor to preserve physical and cognitive aging.
  • 100+ cancer patients treated in phase 1/2 with good safety. ARPA-H awarded $22M for PROSPR healthspan trial.

Technical approach

As reported
Mechanism

Activates estrogen receptor GPER

Selectively activates G protein-coupled estrogen receptor (GPER), regulating aging-related changes in muscle, bone, cardiovascular and cognitive function.

Benefits

Estrogen benefits without sex hormones

Captures estrogen's protective effects on aging tissues without activating nuclear estrogen receptors, avoiding feminization and cancer risk.

Dosing

Once daily oral pill

Small molecule that crosses the blood-brain barrier, allowing once-daily dosing for peripheral and cognitive aging.

Breadth

Multiple aging systems affected

GPER activation influences cardiometabolic, physical capacity, neuroinflammation and senescence.

Primer